Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

Completed

• Conditions: Cardiovascular Diseases; Hyperlipidemias

• Registration Number: NCT02913794
• Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Brief Summary

Fimasartan and Rosuvastatin for hypertension and dyslipidemia control

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-09-21
• Study First Submitted QC: 2016-09-22
• Study First Posted: 2016-09-26
• Study Start: 2016-10-11
• Primary Completion: 2018-03-29
• Study Completion: 2018-03-29
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-08
• Last Update Posted: 2023-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 541

Inclusion Criteria

• Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan at least 12 weeks or more.
• Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at least 12 weeks or more
• Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C, non-HDL-C, * TG) checks 2 weeks before registration

Exclusion Criteria

• Patients being hospitalized
• Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more consecutive days
• Patients who have more than 400mg/dl triglyceride(TG) at the registration time

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Co-relation between blood pressure and dyslipidemia	12 weeks	Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of